Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)
Saudi Arabia · Delayed Price · Currency is SAR 28.98
+0.02 (0.07%)
May 21, 2026, 3:15 PM AST
TADAWUL:2070 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,646 | 1,707 | 1,682 | 1,655 | 1,422 | 1,460 | |
Revenue Growth (YoY) | -2.67% | 1.47% | 1.60% | 16.43% | -2.60% | -6.14% |
Cost of Revenue | 817.84 | 886.06 | 865.95 | 965.8 | 864.5 | 846.73 |
Gross Profit | 827.87 | 820.65 | 816.05 | 689.64 | 557.31 | 613.05 |
Selling, General & Admin | 505.3 | 521.41 | 591.03 | 615.47 | 620.63 | 551.26 |
Research & Development | 58.74 | 60.48 | 76.39 | 41.8 | 42.65 | 29.07 |
Other Operating Expenses | 12.97 | -9.14 | -4.44 | -69.39 | -7.93 | 13.74 |
Operating Expenses | 598.3 | 594.05 | 700.03 | 629.92 | 665.39 | 580.22 |
Operating Income | 229.56 | 226.6 | 116.02 | 59.72 | -108.08 | 32.83 |
Interest Expense | -84.15 | -89.03 | -86.77 | -63.51 | -34.33 | -31.4 |
Interest & Investment Income | 13.2 | 13.2 | 7.66 | 10.59 | - | - |
Earnings From Equity Investments | 23.81 | 24.35 | 22.73 | 20 | 20.44 | 11.41 |
Currency Exchange Gain (Loss) | 3.46 | 3.46 | -10.16 | -4.32 | -14.38 | 15.03 |
Other Non Operating Income (Expenses) | 0.03 | - | - | -3.17 | - | -1.49 |
EBT Excluding Unusual Items | 185.91 | 178.59 | 49.48 | 19.3 | -136.35 | 26.38 |
Gain (Loss) on Sale of Investments | - | - | - | - | 3.63 | 7.81 |
Gain (Loss) on Sale of Assets | 28.7 | 28.7 | 18.94 | 6.38 | 0.14 | -0.45 |
Asset Writedown | - | - | -1.46 | - | - | - |
Legal Settlements | -1.64 | -1.64 | 5.05 | -20.47 | - | - |
Pretax Income | 212.98 | 205.65 | 72.01 | 5.21 | -132.59 | 33.73 |
Income Tax Expense | 23.08 | 8.84 | 40.17 | 45.26 | 25.9 | 12.35 |
Earnings From Continuing Operations | 189.9 | 196.81 | 31.84 | -40.05 | -158.48 | 21.38 |
Earnings From Discontinued Operations | - | - | - | - | -12.75 | -3.28 |
Net Income to Company | 189.9 | 196.81 | 31.84 | -40.05 | -171.23 | 18.1 |
Minority Interest in Earnings | -11.29 | -12.45 | -7.31 | -10.68 | 6.1 | 8.35 |
Net Income | 178.61 | 184.36 | 24.54 | -50.73 | -165.14 | 26.45 |
Net Income to Common | 178.61 | 184.36 | 24.54 | -50.73 | -165.14 | 26.45 |
Net Income Growth | 197.62% | 651.43% | - | - | - | -78.80% |
Shares Outstanding (Basic) | 119 | 119 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 119 | 119 | 120 | 120 | 120 | 120 |
Shares Change (YoY) | -0.57% | -0.15% | -0.08% | -0.31% | - | - |
EPS (Basic) | 1.50 | 1.54 | 0.21 | -0.42 | -1.38 | 0.22 |
EPS (Diluted) | 1.50 | 1.54 | 0.21 | -0.42 | -1.38 | 0.22 |
EPS Growth | 199.32% | 652.54% | - | - | - | -78.80% |
Free Cash Flow | 282.98 | 183.21 | -402.23 | -95.92 | -177.51 | 10.47 |
Free Cash Flow Per Share | 2.38 | 1.53 | -3.37 | -0.80 | -1.48 | 0.09 |
Dividend Per Share | 0.350 | 0.350 | - | - | - | 0.600 |
Dividend Growth | - | - | - | - | - | -40.00% |
Gross Margin | 50.30% | 48.08% | 48.52% | 41.66% | 39.20% | 42.00% |
Operating Margin | 13.95% | 13.28% | 6.90% | 3.61% | -7.60% | 2.25% |
Profit Margin | 10.85% | 10.80% | 1.46% | -3.06% | -11.61% | 1.81% |
Free Cash Flow Margin | 17.20% | 10.73% | -23.91% | -5.79% | -12.48% | 0.72% |
EBITDA | 306.45 | 305.4 | 190.99 | 131.34 | -28.21 | 112.57 |
EBITDA Margin | 18.62% | 17.89% | 11.36% | 7.93% | -1.98% | 7.71% |
D&A For EBITDA | 76.89 | 78.8 | 74.96 | 71.62 | 79.87 | 79.74 |
EBIT | 229.56 | 226.6 | 116.02 | 59.72 | -108.08 | 32.83 |
EBIT Margin | 13.95% | 13.28% | 6.90% | 3.61% | -7.60% | 2.25% |
Effective Tax Rate | 10.84% | 4.30% | 55.78% | 868.21% | - | 36.60% |
Advertising Expenses | - | 39.67 | 33.2 | 56.75 | 41.89 | 40.43 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.